nuvaxovid - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 10h

Clinical Advisor · 7h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

PharmExec · 1d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

· 20h

· 21h

F.D.A. Poised to Restrict Access to Covid Vaccines

· 1d

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

New Trump vaccine policy limits access to COVID shots

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk pending more data on everyone else — raising questions about whether some p...

· 23h

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

· 1d

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

5hon MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of

FDA’s Conditions on NVAX’s COVID-19 Jab

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

Explore more

COVID-19

Novavax

Food and Drug Administration